Treatment of mucosal candidiasis in HIV-infected patients

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mucosal candidiasis is the most common complication of human immunodeficiency virus (HIV) infection, affecting almost all patients at some point during their disease. As the CD4 lymphocyte count falls, especially beyond 300 cells/mm3, the risk of Candida oropharyngeal disease steadily increases. Subsequently, relapse is frequent regardless of HIV stage. Oropharyngeal candidiasis is itself a poor prognostic sign in this population, predicting increased risk of HIV progression and AIDS-defining illness. Symptomatic esophageal candidiasis becomes common as the CD4 count drops below 50 to 100 cells. As a result, Candida esophagitis accounts for 15% of initial AIDS-defining illnesses in adults and adolescents in the United States. This article will review treatment options for mucosal candidiasis, including fluconazole-sensitive mucosal candidiasis, fluconazole-resistant candidiasis, and the role of amphotericin B in this population.

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalJournal de Mycologie Medicale
Volume6
Issue numberSUPPL. 2
StatePublished - 1996

Fingerprint

candidiasis
Candidiasis
Human immunodeficiency virus
HIV
fluconazole
Fluconazole
CD4 Lymphocyte Count
Candida
Acquired Immunodeficiency Syndrome
Therapeutics
esophageal diseases
Esophagitis
amphotericin B
lymphocyte count
relapse
HIV infections
Amphotericin B
Virus Diseases
Population
cells

Keywords

  • amphotericin B
  • esophageal candidiasis
  • HIV
  • mucosal candidiasis
  • prophylaxis
  • thrush
  • treatment

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Microbiology

Cite this

Treatment of mucosal candidiasis in HIV-infected patients. / Zingman, Barry S.

In: Journal de Mycologie Medicale, Vol. 6, No. SUPPL. 2, 1996, p. 3-11.

Research output: Contribution to journalArticle

@article{053f4e96bc204566b2a6ddfcad067810,
title = "Treatment of mucosal candidiasis in HIV-infected patients",
abstract = "Mucosal candidiasis is the most common complication of human immunodeficiency virus (HIV) infection, affecting almost all patients at some point during their disease. As the CD4 lymphocyte count falls, especially beyond 300 cells/mm3, the risk of Candida oropharyngeal disease steadily increases. Subsequently, relapse is frequent regardless of HIV stage. Oropharyngeal candidiasis is itself a poor prognostic sign in this population, predicting increased risk of HIV progression and AIDS-defining illness. Symptomatic esophageal candidiasis becomes common as the CD4 count drops below 50 to 100 cells. As a result, Candida esophagitis accounts for 15{\%} of initial AIDS-defining illnesses in adults and adolescents in the United States. This article will review treatment options for mucosal candidiasis, including fluconazole-sensitive mucosal candidiasis, fluconazole-resistant candidiasis, and the role of amphotericin B in this population.",
keywords = "amphotericin B, esophageal candidiasis, HIV, mucosal candidiasis, prophylaxis, thrush, treatment",
author = "Zingman, {Barry S.}",
year = "1996",
language = "English (US)",
volume = "6",
pages = "3--11",
journal = "Journal de Mycologie Medicale",
issn = "1156-5233",
publisher = "Elsevier Masson",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Treatment of mucosal candidiasis in HIV-infected patients

AU - Zingman, Barry S.

PY - 1996

Y1 - 1996

N2 - Mucosal candidiasis is the most common complication of human immunodeficiency virus (HIV) infection, affecting almost all patients at some point during their disease. As the CD4 lymphocyte count falls, especially beyond 300 cells/mm3, the risk of Candida oropharyngeal disease steadily increases. Subsequently, relapse is frequent regardless of HIV stage. Oropharyngeal candidiasis is itself a poor prognostic sign in this population, predicting increased risk of HIV progression and AIDS-defining illness. Symptomatic esophageal candidiasis becomes common as the CD4 count drops below 50 to 100 cells. As a result, Candida esophagitis accounts for 15% of initial AIDS-defining illnesses in adults and adolescents in the United States. This article will review treatment options for mucosal candidiasis, including fluconazole-sensitive mucosal candidiasis, fluconazole-resistant candidiasis, and the role of amphotericin B in this population.

AB - Mucosal candidiasis is the most common complication of human immunodeficiency virus (HIV) infection, affecting almost all patients at some point during their disease. As the CD4 lymphocyte count falls, especially beyond 300 cells/mm3, the risk of Candida oropharyngeal disease steadily increases. Subsequently, relapse is frequent regardless of HIV stage. Oropharyngeal candidiasis is itself a poor prognostic sign in this population, predicting increased risk of HIV progression and AIDS-defining illness. Symptomatic esophageal candidiasis becomes common as the CD4 count drops below 50 to 100 cells. As a result, Candida esophagitis accounts for 15% of initial AIDS-defining illnesses in adults and adolescents in the United States. This article will review treatment options for mucosal candidiasis, including fluconazole-sensitive mucosal candidiasis, fluconazole-resistant candidiasis, and the role of amphotericin B in this population.

KW - amphotericin B

KW - esophageal candidiasis

KW - HIV

KW - mucosal candidiasis

KW - prophylaxis

KW - thrush

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0030452711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030452711&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030452711

VL - 6

SP - 3

EP - 11

JO - Journal de Mycologie Medicale

JF - Journal de Mycologie Medicale

SN - 1156-5233

IS - SUPPL. 2

ER -